Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin

References

• Alberts, D.S., and Garcia, D.J., 1997. Safety aspects of PEGylated liposomal doxorubicin in patients with cancer. Drugs, 54 (Supplement 4), 30–35.
   PubMedGoogle Scholar
• Ballet, F., et al., 1987. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver. Cancer chemotherapy and pharmacology, 19 (3), 240–245.
   PubMed Web of Science ®Google Scholar
• Banciu, M., Schiffelers, R.M., and Storm, G., 2008. Investigation into the role of tumor-associated macrophages in the antitumor activity of doxil. Pharmaceutical research, 25 (8), 1948–1955.
   PubMed Web of Science ®Google Scholar
• Barui, S., et al., 2014. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials, 35 (5), 1643–1656.
   PubMed Web of Science ®Google Scholar
• Batist, G., 2007. Cardiac safety of liposomal anthracyclines. Cardiovascular toxicology, 7 (2), 72–74.
   PubMed Web of Science ®Google Scholar
• Batist, G., et al., 2001. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of clinical oncology, 19 (5), 1444–1454.
   PubMed Web of Science ®Google Scholar
• Benzer, F., et al., 2018. Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. Journal of biochemical and molecular toxicology [online], 32 (2), e22030. Available from: https://doi.org/10.1002/jbt.22030.
   PubMed Web of Science ®Google Scholar
• Berry, G., et al., 1998. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Annals of oncology, 9 (7), 711–716.
   PubMed Web of Science ®Google Scholar
• Booth, C.L., Brouwer, K.R., and Brouwer, K.L., 1998. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer research, 58 (16), 3641–3648.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., 2019. A W/O emulsion mediated film dispersion method for curcumin encapsulated pH-sensitive liposomes in the colon tumor treatment. Drug development and industrial pharmacy, 45 (2), 282–291.
   PubMed Web of Science ®Google Scholar
• Cui, J., et al., 2007. Direct comparison of two PEGylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Journal of controlled release, 118 (2), 204–215.
   PubMed Web of Science ®Google Scholar
• Deshpande, P.P., Biswas, S., and Torchilin, V.P., 2013. Current trends in the use of liposomes for tumor targeting. Nanomedicine, 8 (9), 1509.
   PubMed Web of Science ®Google Scholar
• Doroshow, J.H., Locker, G.Y., and Myers, C.E., 1980. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. Journal of clinical investigation, 65 (1), 128–135.
   PubMed Web of Science ®Google Scholar
• Fukuda, A., et al., 2017. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One, 12 (9), e0185654.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., et al., 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer research, 54 (4), 987–992.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., et al., 1996. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. Journal of drug targeting, 3 (5), 391–398.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., et al., 1982. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer research, 42 (11), 4734–4739.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., and Papahadjopoulos, D., 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proceedings of the national academy of sciences, 85 (18), 6949–6953.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Shmeeda, H., and Barenholz, Y., 2003. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clinical pharmacokinetics, 42 (5), 419–436.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., et al., 2002. Dose dependency of pharmacokinetics and therapeutic efficacy of PEGylated liposomal doxorubicin (DOXIL) in murine models. Journal of drug targeting, 10 (7), 539–548.
   PubMed Web of Science ®Google Scholar
• Gao, X., et al., 2013. Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer. International journal of nanomedicine, 8, 971–982.
   PubMed Web of Science ®Google Scholar
• Gewirtz, D.A., 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical pharmacology, 57 (7), 727–741.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh, L., et al., 2011. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food and chemical toxicology, 49 (5), 1102–1109.
   PubMed Web of Science ®Google Scholar
• Jain, A., and Rani, V., 2018. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts. Molecular and cellular biochemistry, 442 (1-2), 81–96.
   PubMed Web of Science ®Google Scholar
• Kaminskas, L.M., et al., 2012. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine, 8 (1), 103–111.
   PubMed Web of Science ®Google Scholar
• Le Gal, K., et al., 2015. Antioxidants can increase melanoma metastasis in mice. Science translational medicine, 7 (308), 308re8.
   PubMed Web of Science ®Google Scholar
• Leonard, R.C.F., et al., 2009. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). The breast, 18 (4), 218–224.
   PubMed Web of Science ®Google Scholar
• Lopes-Rodrigues, V., Sousa, E., and Vasconcelos, M.H., 2016. Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives. Pharmaceuticals, 9 (4), 71.
   Web of Science ®Google Scholar
• Lorusso, D., et al., 2007. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (“hand-foot” syndrome). Annals of oncology, 18 (7), 1159–1164.
   PubMed Web of Science ®Google Scholar
• Maheshwari, R.K., et al., 2006. Multiple biological activities of curcumin: a short review. Life sciences, 78 (18), 2081–2087.
   PubMed Web of Science ®Google Scholar
• Menna, P., Salvatorelli, E., and Minotti, G., 2010. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. Chemical research in toxicology, 23 (1), 6–10.
   PubMed Web of Science ®Google Scholar
• Mohajeri, M., and Sahebkar, A., 2018. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review. Critical reviews in oncology/hematology, 122, 30–51.
   PubMed Web of Science ®Google Scholar
• O’Brien, M.E.R., CAELYX Breast Cancer Study Group, et al., 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology, 15, 440–449.
   PubMed Web of Science ®Google Scholar
• Octavia, Y., et al., 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. Journal of molecular and cellular cardiology, 52 (6), 1213–1225.
   PubMed Web of Science ®Google Scholar
• Olson, R.D., and Mushlin, P.S., 1990. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. The faseb journal, 4 (13), 3076–3086.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos, D., et al., 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the national academy of sciences, 88 (24), 11460–11464.
   PubMed Web of Science ®Google Scholar
• Porfire, A., et al., 2015. Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells. Journal of liposome research, 25 (4), 261–269.
   PubMed Web of Science ®Google Scholar
• Prabhakar, U., et al., 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer research, 73 (8), 2412–2417.
   PubMed Web of Science ®Google Scholar
• Sadzuka, Y., et al., 2012. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. International journal of pharmaceutics, 432 (1-2), 42–49.
   PubMed Web of Science ®Google Scholar
• Sesarman, A., et al., 2018. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells. Pharmacological reports, 70 (2), 331–339.
   PubMed Web of Science ®Google Scholar
• Sesarman, A., et al., 2019. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug delivery and translational research, 9 (1), 260–272.
   PubMed Web of Science ®Google Scholar
• Singal, P.K., et al., 1997. Adriamycin cardiomyopathy: pathophysiology and prevention. The faseb journal, 11 (12), 931–936.
   PubMed Web of Science ®Google Scholar
• Soloman, R., and Gabizon, A.A., 2008. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clinical lymphoma and myeloma, 8, 21–32.
   PubMedGoogle Scholar
• Stapleton, S., et al., 2013. Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes. Journal of controlled release, 172 (1), 351–357.
   PubMed Web of Science ®Google Scholar
• Sun, L., et al., 2014. Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Advances, 4 (87), 46737–46750.
   Web of Science ®Google Scholar
• Tahover, E., Patil, Y.P., and Gabizon, A.A., 2015. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-cancer drugs, 26 (3), 241–258.
   PubMed Web of Science ®Google Scholar
• Tardi, P.G., Boman, N.L., and Cullis, P.R., 1996. Liposomal doxorubicin. Journal of drug targeting, 4 (3), 129–140.
   PubMed Web of Science ®Google Scholar
• Tefas, L.R., et al., 2017. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. Drug design, development and therapy, 11, 1605–1621.
   PubMed Web of Science ®Google Scholar
• Tocchetti, C.G., et al., 2014. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. European journal of heart failure, 16 (4), 358–366.
   PubMed Web of Science ®Google Scholar
• Torchilin, V.P., et al., 1994. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochimica et biophysica acta (bba) - biomembranes, 1195 (1), 11–20.
   PubMed Web of Science ®Google Scholar
• Ubezio, P., and Civoli, F., 1994. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free radical biology and medicine, 16, 509–516.
   PubMed Web of Science ®Google Scholar
• Vail, D.M., et al., 2004. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Seminars in oncology, 31, 16–35.
   PubMed Web of Science ®Google Scholar
• Venkatesan, N., 1998. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. British journal of pharmacology, 124 (3), 425–427.
   PubMed Web of Science ®Google Scholar
• Waterhouse, D.N., et al., 2001. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug safety, 24 (12), 903–920.
   PubMedGoogle Scholar
• Wiel, C., et al., 2019. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell, 178 (2), 330–345.e22.
   PubMed Web of Science ®Google Scholar
• Working, P.K., and Dayan, A.D., 1996. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Human and experimental toxicology, 15 (9), 751–785.
   PubMed Web of Science ®Google Scholar
• Young, R.C., Ozols, R.F., and Myers, C.E., 1981. The anthracycline antineoplastic drugs. New England journal of medicine, 305 (3), 139–153.
   PubMed Web of Science ®Google Scholar
• Zhang, D., et al., 2018. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth. International journal of nanomedicine, 13, 4549–4561.
   PubMed Web of Science ®Google Scholar
• Zhou, S., Palmeira, C.M., and Wallace, K.B., 2001. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicology letters, 121 (3), 151–157.
   PubMed Web of Science ®Google Scholar